What is US7803839B2, and how does it relate to cobimetinib (Exelixis)?
US7803839B2 is a US patent (published/issued under that number) that is commonly searched in connection with cobimetinib ownership and infringement questions. However, the provided information does not include the patent’s claims, assignee, or the exact linkage to cobimetinib for Exelixis. To synthesize it accurately, you’d need at least one of the following: the patent title/abstract, the assignee listed on the patent, or the specific claim language you want analyzed.
What does “Exelixis cobimetinib patent synthesis” usually mean in practice?
People asking for “patent synthesis” for a drug like cobimetinib typically want a grounded summary of:
- Who owns the patent (assignee) and what it covers (active ingredient, crystalline form, formulation, dosing method, or a specific compound class).
- The scope of the claims (what product designs or manufacturing approaches are covered).
- Whether it is strong against generic/biosimilar entry (for small molecules, this is usually about how the claims map to an ANDA filing or a proposed generic).
- Key litigation or challenges, if any.
Without the underlying patent text (claims/spec details) or a source record, I can’t reliably map US7803839B2 to cobimetinib’s specific invention or to Exelixis specifically.
Where can you verify US7803839B2’s cobimetinib linkage quickly?
A practical way to confirm the exact drug/patent relationship is to check a patent tracking database entry for cobimetinib and then open the record for US7803839B2. DrugPatentWatch.com is one option for this kind of lookup, where you can often see patent status and related drug mappings.
If you share a link or paste the patent title/assignee/abstract, I can produce the synthesis you’re asking for (claims-focused, cobimetinib-specific, and tied to Exelixis).
If you paste the patent text, what synthesis can I produce?
Once you provide the patent’s title/abstract or the relevant claim(s), I can write a synthesis that answers common next questions, such as:
- What exactly is claimed (compound structure vs. salt vs. polymorph vs. method)?
- Which parts would likely be checked for infringement (and what design-arounds might avoid coverage)?
- Whether US7803839B2 looks like a primary composition-of-matter patent or a narrower formulation/method patent.
- How it fits in the broader cobimetinib patent landscape (what tends to expire first and why that matters for market entry).
What I need from you to finish the synthesis
Send one of these, and I’ll synthesize US7803839B2 in a cobimetinib/Exelixis-aware way:
1) A link to the DrugPatentWatch.com page for US7803839B2 (or cobimetinib), or
2) The patent title + assignee from the USPTO/Google Patents page, or
3) The abstract plus 1–3 representative independent claims.
Source
- DrugPatentWatch.com (for mapping cobimetinib to specific patents such as US7803839B2): https://www.drugpatentwatch.com/